These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22071786)

  • 1. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach.
    Pelosi G; Fabbri A; Bianchi F; Maisonneuve P; Rossi G; Barbareschi M; Graziano P; Cavazza A; Rekhtman N; Pastorino U; Scanagatta P; Papotti M
    J Thorac Oncol; 2012 Feb; 7(2):281-90. PubMed ID: 22071786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
    Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
    Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens.
    Pelosi G; Rossi G; Bianchi F; Maisonneuve P; Galetta D; Sonzogni A; Veronesi G; Spaggiari L; Papotti M; Barbareschi M; Graziano P; Decensi A; Cavazza A; Viale G
    J Thorac Oncol; 2011 Jun; 6(6):1039-49. PubMed ID: 21512408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
    Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
    Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of ΔNp63 expression in lung non-small cell carcinomas.
    Nonaka D
    Am J Surg Pathol; 2012 Jun; 36(6):895-9. PubMed ID: 22367298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
    Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
    J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.
    Nishino M; Hoang MP; Della Pelle P; Morales-Oyarvide V; Huynh TG; Mark EJ; Mino-Kenudson M
    Cancer Cytopathol; 2016 Jul; 124(7):472-84. PubMed ID: 27412420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of p40 (ΔNp63) with p63 and cytokeratin 5/6 immunohistochemistry in non-small cell lung carcinoma fine-needle aspiration biopsy.
    Collins BT; Wang JF; Bernadt CT
    Acta Cytol; 2013; 57(6):619-24. PubMed ID: 24107322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
    Pelosi G; Fabbri A; Papotti M; Rossi G; Cavazza A; Righi L; Tamborini E; Perrone F; Settanni G; Busico A; Testi MA; Maisonneuve P; De Braud F; Garassino M; Valeri B; Sonzogni A; Pastorino U
    J Thorac Oncol; 2015 Nov; 10(11):1560-9. PubMed ID: 26317919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice.
    Rossi G; Pelosi G; Barbareschi M; Graziano P; Cavazza A; Papotti M
    Int J Surg Pathol; 2013 Aug; 21(4):326-36. PubMed ID: 23740564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Characteristics and Prognosis Analysis of Lung Carcinoma With p40/TTF1 Coexpression and Lung Adenosquamous Carcinoma: Lung Carcinoma With p40/TTF1 Coexpression Is a Rare Tumor With High Metastatic Potential.
    Gao R; Zhang X; Chen X; Chen X; Jin L; Zheng H; Yu X
    Int J Surg Pathol; 2024 Oct; 32(7):1286-1291. PubMed ID: 38321785
    [No Abstract]   [Full Text] [Related]  

  • 12. p40 (ΔNp63) and keratin 34βE12 provide greater diagnostic accuracy than p63 in the evaluation of small cell lung carcinoma in small biopsy samples.
    Butnor KJ; Burchette JL
    Hum Pathol; 2013 Aug; 44(8):1479-86. PubMed ID: 23528865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.
    Walia R; Jain D; Madan K; Sharma MC; Mathur SR; Mohan A; Iyer VK; Kumar L
    Indian J Med Res; 2017 Jul; 146(1):42-48. PubMed ID: 29168459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.
    Ao MH; Zhang H; Sakowski L; Sharma R; Illei PB; Gabrielson E; Askin F; Li QK
    Hum Pathol; 2014 May; 45(5):926-34. PubMed ID: 24746197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases.
    Sharma R; Wang Y; Chen L; Gurda GT; Geddes S; Gabrielson E; Askin F; Li QK
    Hum Pathol; 2016 Aug; 54():8-16. PubMed ID: 27045515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells.
    Pelosi G; Fabbri A; Tamborini E; Perrone F; Testi AM; Settanni G; Busico A; Centonze G; Braidotti P; Bulfamante G; De Braud F; Garassino M; Pastorino U
    J Thorac Oncol; 2015 Oct; 10(10):1500-2. PubMed ID: 26398824
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung.
    Uramoto H; Yamada S; Hanagiri T
    Anticancer Res; 2010 Nov; 30(11):4717-20. PubMed ID: 21115930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.
    Terry J; Leung S; Laskin J; Leslie KO; Gown AM; Ionescu DN
    Am J Surg Pathol; 2010 Dec; 34(12):1805-11. PubMed ID: 21107086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation.
    Righi L; Graziano P; Fornari A; Rossi G; Barbareschi M; Cavazza A; Pelosi G; Scagliotti GV; Papotti M
    Cancer; 2011 Aug; 117(15):3416-23. PubMed ID: 21246522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis.
    Vogt AP; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2014 May; 42(5):453-8. PubMed ID: 24166777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.